Brain

electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury

Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury, decrease anxiety and improve motor function…

1 year ago

DiagnaMed Announces Dr. Bassma Ghali as Vice President of Product

Former Reliq Health Technologies Chief Innovation Officer and veteran product leader brings over a decade of experience building and commercializing…

1 year ago

Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate…

1 year ago

Helius Medical Technologies and HealthTech Connex Announce Exclusive Distribution Agreement for the Portable Neuromodulation Stimulator (PoNS®) Device

-- Agreement extends existing partnership ---- Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area…

1 year ago

Lucy Scientific to Acquire SANA-013 Psychedelic Assets from Drug Developer Wesana Health

Transaction subject to Wesana shareholder approval and expected to close in Q2 2023SANA-013 combination of psilocybin and CBD being developed for potential…

1 year ago

Cerevance Announces Presentations at Two Medicinal Chemistry Conferences

BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel…

1 year ago

Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Equity Analyst Coverage by Fundamental Research Corp. with a “Buy” Recommendation

Providence, RI, March 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next generation biopharma company, announces initiation…

1 year ago

Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, March 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),…

1 year ago

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau),…

1 year ago